Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Apoteket omstrukturering AB in connection with the sale of pharmacies
Mandate

Vinge has advised Apoteket omstrukturering AB in connection with the sale of pharmacies

November 10, 2009

Vinge has advised Apoteket Omstrukturering AB in connection with the reregulation of the Swedish pharmacy market and in connection with the disposal through Apoteket AB (publ) of 8 so-called cluster companies consisting of a total of 465 pharmacies to Kronans Droghandel/KF, Altor, Priveq/Investor Growth Capital and Segulah for a total purchase price of approximately SEK 5.9 billion.

The Vinge team was led by Carl Gustaf De Geer and Henrik Wenckert and included associates from different practice areas such as M&A, Banking & Finance, EU &Antitrust, IT/Telecom, Employment & Benefits, Real Estate, Intellectual Property and also entailed regulatory issues regarding the pharmaceuticals legislation including licensing on the pharmacy market.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026